Cipla shares gain 6% on upbeat Q4 numbers
Jefferies has maintained its 'Hold' rating while increasing the price target from ₹1,250 to ₹1,400. "We maintain our Hold rating on the stock, as the company continues to falter on key product launches in the US along with inability to meet its own launch guidance while the stock trades at rich valuation of 24x FY26 EPS," said Jefferies' analysts.
: surged over 6% on Monday after the company's fourth-quarter results beat estimates. Analysts' ratings on the stock after the were mixed with some targeting a 1.5-25.3% upside over Monday's closing price of ₹1,421. The target prices of other suggest 1.1-22.6% downside.Cipla's surged 78.8% and from operations increased by 7.4% in the March quarter from the same period a year ago.
has maintained its 'Buy' rating and has a of ₹1,600, seeing an upside of 12.6% from current levels.
"We continue to like Cipla's healthy outlook in key segments (India, South Africa, the US), delivery on cost efficiencies and prudent capital allocation. Notable pipeline products - inhalers and peptides - provide comfort for the medium-term growth outlook for the US sales," said HSBC's analysts in a note to clients.
has maintained its 'Hold' rating while increasing the price target from ₹1,250 to ₹1,400. "We maintain our Hold rating on the stock, as the company continues to falter on key product launches in the US along with inability to meet its own launch guidance while the stock trades at rich valuation of 24x FY26 EPS," said Jefferies' analysts.
Source: Stocks-Markets-Economic Times
